|Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE||Exec. Chairman, CEO & Pres||105.35k||N/A||1958|
|Ms. Christine Antalik||Chief Financial Officer||282.85k||N/A||1971|
|Mr. Graeme Dick||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Kim Elton||Director of Marketing||N/A||N/A||N/A|
|Mr. Doug Williams MBA||Exec. VP & Chief Bus. Officer||N/A||N/A||N/A|
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-002), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. was founded in 2007 and is headquartered in Guilford, Connecticut.
Bioasis Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.